VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

Tanguy Seiwert, MD
Published: Monday, May 01, 2017



Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

The benefit with immunotherapy agents is a major positive step in the right direction for this field, Seiwert explains. However, it is also a first step as there is a lot of room for improvement and a hope to cure patients in the metastatic setting. There are reports, though, of patients surviving for a long time after achieving deep or complete responses.

The goal must be to continue this approach and move past minor partial responses, Seiwert says.


Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

The benefit with immunotherapy agents is a major positive step in the right direction for this field, Seiwert explains. However, it is also a first step as there is a lot of room for improvement and a hope to cure patients in the metastatic setting. There are reports, though, of patients surviving for a long time after achieving deep or complete responses.

The goal must be to continue this approach and move past minor partial responses, Seiwert says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x